Angioimmunoblastic T Cell Lymphoma Pipeline Insight
DelveInsight’s, “Angioimmunoblastic T-cell lymphoma – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T-cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Angioimmunoblastic T-cell lymphoma Understanding
Angioimmunoblastic T-cell lymphoma: Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a type of peripheral T-cell lymphoma arising from follicular helper T cells of the germinal center. AITL is characterized by the transformation of a T-cell into a malignant cell. It is a systemic disease that is present with generalized lymphadenopathy, hepatosplenomegaly, constitutional symptoms, skin rash, anemia, and polyclonal hypergammaglobulinemia. The Abnormal, uncontrolled growth and multiplication (proliferation) of malignant T-cells may lead to enlargement of a specific lymph node region or regions.
The symptoms of Angioimmunoblastic T-cell lymphoma include:
- high fever
- night sweats
- skin rash
- enlargement of a specific lymph node region or regions
- autoimmune disorders such as autoimmune hemolytic anemia and immune thrombocytopenia
Diagnosis of Angioimmunoblastic T-cell lymphoma (AITL) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a biopsy of an affected lymph node or other affected areas such as the skin or bone marrow. A series of other tests may be done to determine the extent, or stage, of the disease such as blood tests, specialized imaging tests and bone marrow examination. Specialized imaging techniques may include magnetic resonance imaging (MRI), computed tomography (CT) scanning, and positron emission tomography (PET scan).
Treatment of Angioimmunoblastic T-cell lymphoma is based on the assessment of the extent or “stage” of the disease progression, tumor size, presence or absence of certain symptoms, an individual’s age and general health. It will help in characterizing the potential disease course and appropriate treatment approaches.A combination of chemotherapy and immunotherapy (chemoimmunotherapy) have been used. Corticosteroids, such as prednisone, are used to treat the symptoms of AITL that result from dysfunction of the immune system. Investigational therapies includes low dose methotexate with corticosteroids, thalidomide, lenalidomide, bevacizumab, alemtuzumab, fludarabine and 2-chlordeoxyadenosine. The use of interferon alfa in association with or following chemotherapy is also under evaluation.
Angioimmunoblastic T-cell lymphoma Emerging Drugs Chapters
This segment of the Angioimmunoblastic T-cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angioimmunoblastic T-cell lymphoma Emerging Drugs
- Tipifarnib: Kura Oncology
Tipifarnib, is a potent and highly selective inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development. The therapy was in-licensed from Janssen in December 2014. In March 2020 Kura Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL).
AUTO4 is a programmed T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1, a novel and differentiated treatment approach.
AUTO4 is designed to selectively kill cancerous T cells in a manner will preserve a portion of the patient’s normal, healthy T cells to maintain immunity.
AUTO4 is currently in a Phase I study in TRBC1-positive peripheral T cell lymphoma.
Further product details are provided in the report……..
Angioimmunoblastic T-cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Angioimmunoblastic T-cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Angioimmunoblastic T-cell lymphoma
There are approx. 10+ key companies which are developing the therapies for Angioimmunoblastic T-cell lymphoma. The companies which have their Angioimmunoblastic T-cell lymphoma drug candidates in the most advanced stage, i.e. phase II include, Kura Oncology.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Angioimmunoblastic T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Angioimmunoblastic T-cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioimmunoblastic T-cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioimmunoblastic T-cell lymphoma drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Angioimmunoblastic T-cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Angioimmunoblastic T-cell lymphoma.
Angioimmunoblastic T-cell lymphoma Report Insights
- Angioimmunoblastic T-cell lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Angioimmunoblastic T-cell lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Angioimmunoblastic T-cell lymphoma drugs?
- How many Angioimmunoblastic T-cell lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angioimmunoblastic T-cell lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angioimmunoblastic T-cell lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Angioimmunoblastic T-cell lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kura Oncology
- Bristol-Myers Squibb
- PersonGen Biotherapeutics
- Arno Therapeutics
- Fenretinide intravenous
- CD7-CAR-T cells